"rationale","uuid:ID","versionIdentifier","id","instanceType"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","757f136f-7e1a-4ac3-a4cb-3fa5a611e33e","2","StudyVersion_1","StudyVersion"
